Trial Profile
A 24-week, Three-site, Randomized, Double Blind, Placebo Controlled, Parallel Group, Proof-of-concept Study to Evaluate Rasagiline in the Regional Brain Metabolism on FDG PET in Patients With Mild to Moderate Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Oct 2020
Price :
$35
*
At a glance
- Drugs Rasagiline (Primary)
- Indications Alzheimer's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms R2
- 06 May 2019 Status changed from active, no longer recruiting to completed.
- 03 Apr 2018 Planned primary completion date changed from 15 Feb 2018 to 15 Feb 2019.
- 03 Apr 2018 Status changed from recruiting to active, no longer recruiting.